Journal of International Oncology ›› 2023, Vol. 50 ›› Issue (3): 138-143.doi: 10.3760/cma.j.cn371439-20221214-00028
• Original Articles • Previous Articles Next Articles
Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun()
Received:
2022-12-14
Revised:
2023-01-18
Online:
2023-03-08
Published:
2023-04-12
Contact:
Xu Jiankun, Email: Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun. Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases[J]. Journal of International Oncology, 2023, 50(3): 138-143.
"
基线特征 | 例数(%) |
---|---|
性别 | |
男 | 14(66.67) |
女 | 7(33.33) |
年龄(岁) | |
>60 | 12(57.14) |
≤60 | 9(42.86) |
原发肿瘤 | |
非小细胞肺癌 | 12(57.14) |
小细胞肺癌 | 1(4.76) |
乳腺癌 | 3(14.30) |
直肠癌 | 2(9.52) |
肾癌 | 2(9.52) |
卵巢癌 | 1(4.76) |
基线特征 | 例数(%) |
原发灶病理类型 | |
腺癌 | 11(52.38) |
鳞状细胞癌 | 4(19.04) |
浸润性导管癌 | 3(14.30) |
透明细胞癌 | 2(9.52) |
小细胞癌 | 1(4.76) |
病灶个数 | |
1 | 12(57.14) |
2~4 | 7(33.33) |
5~10 | 2(9.52) |
病灶最大直径(cm) | |
<2 | 16(76.19) |
2~3 | 5(23.81) |
病灶最大体积(cm3) | |
<4 | 14(66.67) |
4~6 | 7(33.33) |
DS-GPA评分(分) | |
≤2 | 10(47.62) |
>2 | 11(52.38) |
全身治疗 | |
是 | 16(76.19) |
否 | 5(23.81) |
[1] |
Lamba N, Wen PY, Aizer AA. Epidemiology of brain metastases and leptomeningeal disease[J]. Neuro Oncol, 2021, 23(9): 1447-1456. DOI: 10.1093/neuonc/noab101.
doi: 10.1093/neuonc/noab101 |
[2] |
Garsa A, Jang JK, Baxi S, et al. Radiation therapy for brain metastases: a systematic review[J]. Pract Radiat Oncol, 2021, 11(5): 354-365. DOI: 10.1016/j.prro.2021.04.002.
doi: 10.1016/j.prro.2021.04.002 pmid: 34119447 |
[3] |
July J, Pranata R. Hypofractionated versus single-fraction stereotactic radiosurgery for the treatment of brain metastases: a systematic review and meta-analysis[J]. Clin Neurol Neurosurg, 2021, 206: 106645. DOI: 10.1016/j.clineuro.2021.106645.
doi: 10.1016/j.clineuro.2021.106645 |
[4] |
Masucci GL. Hypofractionated radiation therapy for large brain metastases[J]. Front Oncol, 2018, 8: 379. DOI: 10.3389/fonc.2018.00379.
doi: 10.3389/fonc.2018.00379 pmid: 30333955 |
[5] |
Sarmey N, Kaisman-Elbaz T, Mohammadi AM. Management strategies for large brain metastases[J]. Front Oncol, 2022, 12: 827304. DOI: 10.3389/fonc.2022.827304.
doi: 10.3389/fonc.2022.827304 |
[6] |
Tonse R, Tom MC, Mehta MP, et al. Integration of systemic therapy and stereotactic radiosurgery for brain metastases[J]. Cancers (Basel), 2021, 13(15): 3682. DOI: 10.3390/cancers13153682.
doi: 10.3390/cancers13153682 |
[7] |
Lupattelli M, Tini P, Nardone V, et al. Stereotactic radiotherapy for brain oligometastases[J]. Rep Pract Oncol Radiother, 2022, 27(1): 15-22. DOI: 10.5603/RPOR.a2021.0133.
doi: 10.5603/RPOR.a2021.0133 |
[8] |
周冲, 郭汝元, 夏铀铀, 等. 基于直线加速器的分次立体定向放疗在脑寡转移肿瘤中的应用[J]. 肿瘤研究与临床, 2020, 32(11): 741-744. DOI: 10.3760/cma.j.cn115355-20200401-00166.
doi: 10.3760/cma.j.cn115355-20200401-00166 |
[9] |
中国放射性脑损伤多学科协作组; 中国医师协会神经内科分会脑与脊髓损害专业委员会. 放射性脑损伤诊治中国专家共识[J]. 中华神经医学杂志, 2019, 18(6): 541-549. DOI: 10.3760/cma.j.issn.1671-8925.2019.06.001.
doi: 10.3760/cma.j.issn.1671-8925.2019.06.001 |
[10] |
Mohammadi AM, Schroeder JL, Angelov L, et al. Impact of the radiosurgery prescription dose on the local control of small (2 cm or smaller) brain metastases[J]. J Neurosurg, 2017, 126(3): 735-743. DOI: 10.3171/2016.3.JNS153014.
doi: 10.3171/2016.3.JNS153014 pmid: 27231978 |
[11] |
Baschnagel AM, Meyer KD, Chen PY, et al. Tumor volume as a predictor of survival and local control in patients with brain metastases treated with Gamma Knife surgery[J]. J Neurosurg, 2013, 119(5): 1139-1144. DOI: 10.3171/2013.7.JNS13431.
doi: 10.3171/2013.7.JNS13431 pmid: 23971958 |
[12] |
Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline[J]. J Clin Oncol, 2022, 40(5): 492-516. DOI: 10.1200/JCO.21.02314.
doi: 10.1200/JCO.21.02314 |
[13] |
Gondi V, Bauman G, Bradfield L, et al. Radiation therapy for brain metastases: an ASTRO clinical practice guideline[J]. Pract Radiat Oncol, 2022, 12(4): 265-282. DOI: 10.1016/j.prro.2022.02.003.
doi: 10.1016/j.prro.2022.02.003 pmid: 35534352 |
[14] |
Remick JS, Kowalski E, Khairnar R, et al. A multi-center analysis of single-fraction versus hypofractionated stereotactic radiosurgery for the treatment of brain metastasis[J]. Radiat Oncol, 2020, 15(1): 128. DOI: 10.1186/s13014-020-01522-6.
doi: 10.1186/s13014-020-01522-6 pmid: 32466775 |
[15] |
Zhou C, Xia Y, Huang P, et al. Fractionated stereotactic radiation therapy using volumetric modulated arc therapy in patients with solitary brain metastases[J]. Biomed Res Int, 2020, 2020: 6342057. DOI: 10.1155/2020/6342057.
doi: 10.1155/2020/6342057 |
[16] |
Myrehaug S, Hudson J, Soliman H, et al. Hypofractionated stereotactic radiation therapy for intact brain metastases in 5 daily fractions: effect of dose on treatment response[J]. Int J Radiat Oncol Biol Phys, 2022, 112(2): 342-350. DOI: 10.1016/j.ijrobp.2021.09.003.
doi: 10.1016/j.ijrobp.2021.09.003 |
[17] |
Milano MT, Grimm J, Niemierko A, et al. Single- and multifraction stereotactic radiosurgery dose/volume tolerances of the brain[J]. Int J Radiat Oncol Biol Phys, 2021, 110(1): 68-86. DOI: 10.1016/j.ijrobp.2020.08.013.
doi: 10.1016/j.ijrobp.2020.08.013 |
[18] |
Lehrer EJ, Peterson JL, Zaorsky NG, et al. Single versus multifraction stereotactic radiosurgery for large brain metastases: an international meta-analysis of 24 trials[J]. Int J Radiat Oncol Biol Phys, 2019, 103(3): 618-630. DOI: 10.1016/j.ijrobp.2018.10.038.
doi: 10.1016/j.ijrobp.2018.10.038 |
[19] |
Andruska N, Kennedy WR, Bonestroo L, et al. Dosimetric predictors of symptomatic radiation necrosis after five-fraction radiosurgery for brain metastases[J]. Radiother Oncol, 2021, 156: 181-187. DOI: 10.1016/j.radonc.2020.12.011.
doi: 10.1016/j.radonc.2020.12.011 |
[20] |
Yan M, Holden L, Wang M, et al. Gamma knife icon based hypofractionated stereotactic radiosurgery (GKI-HSRS) for brain metastases: impact of dose and volume[J]. J Neurooncol, 2022, 159(3): 705-712. DOI: 10.1007/s11060-022-04115-3.
doi: 10.1007/s11060-022-04115-3 |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156. |
[4] | Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376. |
[5] | Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy (2023 version) [J]. Journal of International Oncology, 2023, 50(4): 193-201. |
[6] | Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng. Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy [J]. Journal of International Oncology, 2023, 50(12): 745-750. |
[7] | Ma Xueyan, Lu Lili, Sun Pengfei. Advances in the immune microenvironment in cervical cancer [J]. Journal of International Oncology, 2023, 50(1): 47-50. |
[8] | Li Zhilei, Luo Jialin. Biological indexes for predicting sensitivity of preoperative concurrent chemoradiotherapy for locally advanced rectal cancer [J]. Journal of International Oncology, 2022, 49(9): 564-567. |
[9] | Wu Puyuan, Qi Liang, Wang Tao, Shi Minke, Sun Yuwei, Wang Lifeng, Liu Baorui, Yan Jing, Ren Wei. Efficacy of postoperative radiotherapy based on modified clinical target volume according to high-frequency recurrence regions in patients with esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(8): 464-472. |
[10] | Xia Lingling, Chen Yongshun, Li Bin, Ning Tingting, Zhang Caiyutian. Comparison of safety and efficacy between chemoradiotherapy and chemotherapy after R0 resection in pN+ esophageal squamous cell carcinoma patients [J]. Journal of International Oncology, 2022, 49(6): 334-339. |
[11] | Xiao Nan, Sun Pengfei. Research progress of oxidative stress in the sensitivity of chemoradiotherapy for gliomas [J]. Journal of International Oncology, 2022, 49(6): 357-361. |
[12] | Ye Qian, Ling Zhi, Liu Shenxiang, Lu Guotao, Yin Xudong. Effects of sarcopenia on the clinical efficacy and prognosis of radical radiotherapy in elderly patients with esophageal cancer [J]. Journal of International Oncology, 2022, 49(4): 199-205. |
[13] | Sun Xiaolin, Zhang Zhanyu, Xu Linzong, Liu Yingchao, Li Xiaomei. Potential value of radiotherapy combined with immunotherapy in breast cancer brain metastases [J]. Journal of International Oncology, 2022, 49(4): 243-246. |
[14] | Huang Huayu, Song Qibin, Gong Hongyun, Song Jia. Analysis on the incidence and risk factors of pneumonia in patients with lung cancer receiving thoracic radiotherapy and immunotherapy [J]. Journal of International Oncology, 2022, 49(12): 718-723. |
[15] | Kong Chunyu, Sun Pengfei. SLC7A11 and glioma [J]. Journal of International Oncology, 2022, 49(10): 604-607. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||